• MaxCyte raised full-year 2026 revenue guidance to about $34 million from $30 million-$32 million.
• Core business revenue outlook increased to about $28 million from $25 million-$27 million.
• SPL Program-related revenue forecast lifted to about $6 million from about $5 million, including about $4 million milestones, $2 million royalties.
• Preliminary Q3 core business revenue seen at about $8.1 million, up 26% year over year.
• Preliminary Q3 SPL Program-related revenue exceeded $1 million, including a $1 million milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140805PRIMZONEFULLFEED9845307) on October 14, 2026, and is solely responsible for the information contained therein.